Who are Amlodipine plus Hydrochlorothiazide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Perindopril + amlodipine + if necessary, hydrochlorothiazide, Amlodipine + HCTZ.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amlodipine-plus-hydrochlorothiazide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Amlodipine plus Hydrochlorothiazide — Competitive Intelligence Brief

Amlodipine plus Hydrochlorothiazide (Amlodipine plus Hydrochlorothiazide) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker + thiazide diuretic combination. Area: Cardiovascular.

marketed Calcium channel blocker + thiazide diuretic combination L-type voltage-gated calcium channel (amlodipine); sodium-chloride cotransporter (hydrochlorothiazide) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Amlodipine plus Hydrochlorothiazide (Amlodipine plus Hydrochlorothiazide) — University of Abuja. Amlodipine relaxes blood vessels by blocking calcium channels, while hydrochlorothiazide reduces blood volume by increasing sodium and water excretion through the kidneys, together lowering blood pressure.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Amlodipine plus Hydrochlorothiazide TARGET	Amlodipine plus Hydrochlorothiazide	University of Abuja	marketed	Calcium channel blocker + thiazide diuretic combination	L-type voltage-gated calcium channel (amlodipine); sodium-chloride cotransporter (hydrochlorothiazide)
Perindopril + amlodipine + if necessary, hydrochlorothiazide	Perindopril + amlodipine + if necessary, hydrochlorothiazide	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	marketed	ACE inhibitor + calcium channel blocker + thiazide diuretic combination	Angiotensin-converting enzyme (ACE), L-type calcium channels, sodium-chloride cotransporter
Amlodipine + HCTZ	Amlodipine + HCTZ	Novartis	phase 3	Calcium channel blocker + thiazide diuretic combination	L-type voltage-gated calcium channel (amlodipine); sodium-chloride cotransporter (HCTZ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker + thiazide diuretic combination class)

Novartis · 1 drug in this class
University of Abuja · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amlodipine plus Hydrochlorothiazide — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine-plus-hydrochlorothiazide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab